Rhumbline Advisers grew its holdings in shares of Genomic Health, Inc. (NASDAQ:GHDX) by 5.5% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 24,664 shares of the medical research company’s stock after acquiring an additional 1,296 shares during the period. Rhumbline Advisers owned about 0.07% of Genomic Health worth $803,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also modified their holdings of GHDX. Teachers Advisors LLC grew its position in shares of Genomic Health by 6.1% during the 4th quarter. Teachers Advisors LLC now owns 31,801 shares of the medical research company’s stock valued at $935,000 after acquiring an additional 1,838 shares during the period. Russell Investments Group Ltd. grew its position in shares of Genomic Health by 25.4% during the 1st quarter. Russell Investments Group Ltd. now owns 24,322 shares of the medical research company’s stock valued at $766,000 after acquiring an additional 4,925 shares during the period. Bank of New York Mellon Corp grew its position in shares of Genomic Health by 0.6% during the 1st quarter. Bank of New York Mellon Corp now owns 88,577 shares of the medical research company’s stock valued at $2,789,000 after acquiring an additional 500 shares during the period. Airain ltd bought a new stake in shares of Genomic Health during the 1st quarter valued at $285,000. Finally, Envestnet Asset Management Inc. grew its position in shares of Genomic Health by 13.6% during the 1st quarter. Envestnet Asset Management Inc. now owns 8,282 shares of the medical research company’s stock valued at $259,000 after acquiring an additional 993 shares during the period. 88.90% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: “Rhumbline Advisers Acquires 1,296 Shares of Genomic Health, Inc. (GHDX)” was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another domain, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The legal version of this story can be accessed at https://www.thecerbatgem.com/2017/09/28/rhumbline-advisers-acquires-1296-shares-of-genomic-health-inc-ghdx.html.

In related news, insider Phillip G. Febbo sold 3,174 shares of the firm’s stock in a transaction on Wednesday, July 19th. The shares were sold at an average price of $33.57, for a total transaction of $106,551.18. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Kimberly J. Popovits sold 5,000 shares of the firm’s stock in a transaction on Monday, August 14th. The shares were sold at an average price of $30.22, for a total transaction of $151,100.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 42,642 shares of company stock worth $1,343,081. 46.20% of the stock is owned by company insiders.

Genomic Health, Inc. (NASDAQ GHDX) opened at 31.49 on Thursday. The company’s market cap is $1.09 billion. Genomic Health, Inc. has a one year low of $26.37 and a one year high of $33.97. The company has a 50-day moving average of $30.86 and a 200 day moving average of $31.62.

Genomic Health (NASDAQ:GHDX) last released its quarterly earnings results on Tuesday, August 1st. The medical research company reported ($0.08) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.06) by ($0.02). The firm had revenue of $85.50 million for the quarter, compared to analyst estimates of $86.08 million. Genomic Health had a negative net margin of 1.50% and a negative return on equity of 4.33%. The firm’s quarterly revenue was up 4.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.18) EPS. Analysts anticipate that Genomic Health, Inc. will post ($0.01) earnings per share for the current year.

Several research analysts recently weighed in on the stock. Canaccord Genuity reaffirmed a “buy” rating and issued a $35.00 target price on shares of Genomic Health in a report on Wednesday. Jefferies Group LLC reaffirmed a “hold” rating and issued a $33.00 target price on shares of Genomic Health in a report on Monday, June 12th. BidaskClub downgraded shares of Genomic Health from a “hold” rating to a “sell” rating in a report on Friday, August 4th. Piper Jaffray Companies reaffirmed a “hold” rating and issued a $31.00 target price on shares of Genomic Health in a report on Thursday, August 3rd. Finally, Zacks Investment Research downgraded shares of Genomic Health from a “hold” rating to a “sell” rating in a report on Tuesday, August 1st. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating and one has issued a buy rating to the stock. Genomic Health currently has an average rating of “Hold” and an average price target of $32.00.

About Genomic Health

Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.

Want to see what other hedge funds are holding GHDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Genomic Health, Inc. (NASDAQ:GHDX).

Institutional Ownership by Quarter for Genomic Health (NASDAQ:GHDX)

Receive News & Stock Ratings for Genomic Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health Inc. and related stocks with our FREE daily email newsletter.